Table 5

Impact of duration of treatment effect on treatment choice (threshold £20 000 per QALY gained)

Subgroup	Duration of mortality treatment effect				Lifetime mortality and constant HRQoL
Subgroup	Lifetime	7.5 years	5 years	Mean f/up	Lifetime mortality and constant HRQoL
Individuals without LBBB
NYHA I, QRS <120 ms*	ICD	MT	MT	MT	ICD
NYHA I, QRS ≥120 ms and <150 ms*	ICD	ICD	ICD	ICD	ICD
NYHA I, QRS ≥150 ms*	CRT-D	MT	MT	MT	CRT-D
NYHA II, QRS <120 ms	ICD	MT	MT	MT	ICD
NYHA II, QRS ≥120 ms and <150 ms	ICD	ICD	ICD	ICD	ICD
NYHA II, QRS ≥150 ms	CRT-D	MT	MT	MT	ICD
NYHA III, QRS <120 ms	MT	MT	MT	MT	MT
NYHA III, QRS ≥120 ms and <150 ms	CRT-P	MT	MT	MT	CRT-P
NYHA III, QRS ≥150 ms	CRT-P	CRT-P	CRT-P	CRT-P	CRT-P
NYHA IV, QRS <120 ms	MT	MT	MT	MT	MT
NYHA IV, QRS ≥120 ms and <150 ms	MT	MT	MT	MT	MT
NYHA IV, QRS ≥150 ms	CRT-P	CRT-P	CRT-P	CRT-P	CRT-P
Individuals with LBBB
NYHA I, QRS ≥120 ms and <150 ms*	CRT-D	MT	MT	MT	CRT-D
NYHA I, QRS ≥150 ms*	CRT-D	CRT-D	CRT-D	MT	CRT-D
NYHA II, QRS ≥120 ms and <150 ms	CRT-D	MT	MT	MT	CRT-D
NYHA II, QRS ≥150 ms	CRT-D	CRT-D	CRT-D	MT	CRT-D
NYHA III, QRS ≥120 ms and <150 ms	CRT-P	CRT-P	CRT-P	CRT-P	CRT-P
NYHA III, QRS ≥150 ms	CRT-P	CRT-P	CRT-P	CRT-P	CRT-P
NYHA IV, QRS ≥120 ms and <150 ms	CRT-P	CRT-P	CRT-P	CRT-P	CRT-P
NYHA IV, QRS ≥150 ms	CRT-P	CRT-P	CRT-P	CRT-P	CRT-P

Changes from base case highlighted in bold.
*Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; HRQoL, health-related quality of life; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; MT, medical therapy; NYHA, New York Heart Association; QALY, quality-adjusted life-year.